Agilent Technologies Valuation
Is A * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A * (MX$2421.87) is trading above our estimate of fair value (MX$2258.62)
Significantly Below Fair Value: A * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A *?
Other financial metrics that can be useful for relative valuation.
What is A *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$38.83b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.1x |
Enterprise Value/EBITDA | 24.7x |
PEG Ratio | 4.1x |
Price to Earnings Ratio vs Peers
How does A *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 40.7x | ||
IQV IQVIA Holdings | 28.6x | 12.9% | US$38.5b |
MTD Mettler-Toledo International | 38.6x | 8.3% | US$30.5b |
LONN Lonza Group | 53.6x | 20.6% | CHF 35.1b |
WST West Pharmaceutical Services | 42.1x | 10.6% | US$23.6b |
A * Agilent Technologies | 30.7x | 7.5% | Mex$38.8b |
Price-To-Earnings vs Peers: A * is good value based on its Price-To-Earnings Ratio (30.7x) compared to the peer average (40.7x).
Price to Earnings Ratio vs Industry
How does A *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: A * is good value based on its Price-To-Earnings Ratio (30.7x) compared to the Global Life Sciences industry average (31.3x).
Price to Earnings Ratio vs Fair Ratio
What is A *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 30.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,421.87 | Mex$2,562.57 +5.8% | 6.9% | Mex$2,840.25 | Mex$2,290.53 | n/a | 16 |
Jun ’25 | n/a | Mex$2,398.49 0% | 7.2% | Mex$2,634.40 | Mex$2,124.51 | n/a | 17 |
May ’25 | n/a | Mex$2,580.12 0% | 6.2% | Mex$2,817.23 | Mex$2,219.63 | n/a | 18 |
Apr ’25 | n/a | Mex$2,460.98 0% | 7.5% | Mex$2,761.13 | Mex$2,091.76 | n/a | 18 |
Mar ’25 | n/a | Mex$2,476.22 0% | 7.7% | Mex$2,821.20 | Mex$2,137.28 | n/a | 17 |
Feb ’25 | n/a | Mex$2,404.06 0% | 8.1% | Mex$2,841.71 | Mex$2,066.70 | n/a | 17 |
Jan ’25 | n/a | Mex$2,310.05 0% | 11.1% | Mex$2,816.43 | Mex$1,706.93 | n/a | 18 |
Dec ’24 | n/a | Mex$2,285.09 0% | 10.2% | Mex$2,597.11 | Mex$1,719.94 | n/a | 17 |
Nov ’24 | n/a | Mex$2,499.81 0% | 11.4% | Mex$2,960.75 | Mex$1,907.23 | n/a | 17 |
Oct ’24 | n/a | Mex$2,452.15 0% | 10.3% | Mex$2,861.50 | Mex$1,843.30 | n/a | 17 |
Sep ’24 | n/a | Mex$2,413.86 0% | 9.3% | Mex$2,779.36 | Mex$1,875.64 | n/a | 17 |
Aug ’24 | n/a | Mex$2,397.70 0% | 9.1% | Mex$2,729.34 | Mex$1,925.61 | n/a | 17 |
Jul ’24 | n/a | Mex$2,479.20 0% | 7.6% | Mex$2,792.29 | Mex$2,158.46 | n/a | 17 |
Jun ’24 | n/a | Mex$2,605.40 0% | 7.9% | Mex$3,007.03 | Mex$2,228.74 | n/a | 17 |
May ’24 | n/a | Mex$2,936.74 0% | 7.3% | Mex$3,154.27 | Mex$2,302.26 | n/a | 17 |
Apr ’24 | n/a | Mex$2,953.04 0% | 7.0% | Mex$3,149.90 | Mex$2,299.07 | n/a | 16 |
Mar ’24 | Mex$2,660.00 | Mex$2,953.04 +11.0% | 7.0% | Mex$3,149.90 | Mex$2,299.07 | n/a | 16 |
Feb ’24 | Mex$2,660.00 | Mex$3,034.57 +14.1% | 6.8% | Mex$3,174.63 | Mex$2,371.64 | n/a | 16 |
Jan ’24 | Mex$2,660.00 | Mex$3,169.20 +19.1% | 6.9% | Mex$3,360.71 | Mex$2,510.65 | n/a | 16 |
Dec ’23 | Mex$2,660.00 | Mex$3,049.35 +14.6% | 6.9% | Mex$3,256.47 | Mex$2,432.77 | n/a | 16 |
Nov ’23 | Mex$2,660.00 | Mex$2,978.12 +12.0% | 8.6% | Mex$3,392.16 | Mex$2,294.70 | n/a | 16 |
Oct ’23 | Mex$2,660.00 | Mex$3,012.88 +13.3% | 8.5% | Mex$3,424.58 | Mex$2,316.63 | n/a | 16 |
Sep ’23 | Mex$2,660.00 | Mex$3,012.88 +13.3% | 8.5% | Mex$3,424.58 | Mex$2,316.63 | n/a | 16 |
Aug ’23 | Mex$2,660.00 | Mex$2,965.65 +11.5% | 8.6% | Mex$3,490.51 | Mex$2,361.23 | n/a | 16 |
Jul ’23 | Mex$2,660.00 | Mex$2,979.25 +12.0% | 10.5% | Mex$3,495.99 | Mex$2,297.37 | n/a | 15 |
Jun ’23 | Mex$2,660.00 | Mex$2,945.02 +10.7% | 10.4% | Mex$3,448.11 | Mex$2,265.90 | n/a | 15 |
Analyst Forecast: Target price is less than 20% higher than the current share price.